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Abstract We identified four cannabimimetic indazole and
indole derivatives in new illegal psychoactive substances




zyl)-1H-indole-3-carboxamide (AB-FUBICA, 2), N-(1-
amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-
1H-indole-3-carboxamide (ADB-FUBICA, 3), and N-(1-
amino-3-methyl-1-oxobutan-2-yl)-1-benzyl-1H-indole-3-
carboxamide (AB-BICA, 4). These compounds were iden-
tified by liquid chromatography–high-resolution mass
spectrometry, gas chromatography–mass spectrometry, and
nuclear magnetic resonance spectroscopy. No chemical or
pharmacological data about compound 4 has appeared until
now, making this the first report on this compound. Com-
pounds 1, 2, and 3 have previously been reported to have a
high affinity for cannabinoid CB1 and CB2 receptors, but this
is the first report of their presence in illegal products.
Keywords N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
benzyl-1H-indazole-3-carboxamide (ADB-BINACA)  N-
(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-
1H-indole-3-carboxamide (AB-FUBICA)  N-(1-Amino-
3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
indole-3-carboxamide (ADB-FUBICA)  N-(1-Amino-3-
methyl-1-oxobutan-2-yl)-1-benzyl-1H-indole-3-
carboxamide (AB-BICA)  Synthetic cannabinoid 
New psychoactive substance
Introduction
A wide variety of new psychoactive substances (NPSs) has
emerged around the world over the past few years, and
many of the existing drugs have been replaced by other
new drugs in a short period of time [1–6]. By July 2015, 96
countries and territories reported over 540 NPSs to
UNODC, far exceeding the 234 substances currently con-
trolled under the International Drug Conventions [3].
Synthetic cannabinoids are cannabimimetic compounds
originally synthesized for medical research, but now have
become the largest and most dynamic group of NPSs. Since
the identification of the first synthetic cannabinoid in 2008,
more than 130 synthetic cannabinoids have been reported
to the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) [1]. According to the UNODC
Global Synthetic Monitoring: Analyses, Reporting, and
Trends (SMART) program, 184 synthetic cannabinoids
(34 % of the total number of NPSs reported worldwide)
have been detected as psychoactive ingredients in herbal
products or chemical powder around the world up to now
[3].
In June 2015, a clandestine laboratory was dismantled in
Hubei Province of China, and about 20 kg of NPS powder
samples were seized. About 200 unknown samples were
submitted to the national narcotic laboratory of Minister of
Public Security for analysis. After a series of complicated
analyses using liquid chromatography–high-resolution
mass spectrometry (LC–HR-MS), gas chromatography–
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mass spectrometry (GC–MS), and nuclear magnetic reso-
nance spectroscopy (NMR), about 30 species of synthetic
cannabinoids were disclosed, including four new types of
synthetic cannabinoids, which were N-(1-amino-3,3-dime-
thyl-1-oxobutan-2-yl)-1-benzyl-1H-indazole-3-carboxam-




FUBICA, 3), and N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-benzyl-1H-indole-3-carboxamide (AB-BICA, 4). All of
them represent the indazole or indole analogues of AB-
FUBINACA or ADB-FUBINACA [7–10]. There has been
no synthetic, chemical, or biological information about
compound 4 until now; this is the first report of this
compound. Compounds 1 and 2/3 were synthesized by
Pfizer in 2009 [10] and Banister in 2015 [7], respectively,
and were reported as potent cannabinoid CB1 and CB2
receptor modulators. This is the first report of their detec-
tion in illegal products and their mass spectra are discussed
in detail in this article. The structures of compounds 1–4
were elucidated by comparing to the LC–MS, GC–MS, and




In this article, we described our identification of the four
newly detected synthetic cannabinoid compounds in detail.
The structures of compounds 1–5 are shown in Fig. 1.
Materials and methods
Chemicals and reagents
Methanol and formic acid were obtained from Merck
Chemicals (Darmstadt, Germany). Acetonitrile was
obtained from Fisher Scientific (Aalst, Belgium). Deuter-
ated dimethyl sulfoxide (DMSO-d6, 99.9 %) was pur-
chased from Cambridge Isotope Laboratories (Tewksbury,
MA, USA). All solvents and reagents used in the analyses
were of HPLC grade. Distilled water was obtained by
reverse diffusion in a Millipore system (EMD Millipore,
Billerica, MA, USA).
Sample preparation
For GC–MS analysis, 5 mg of the powder-type product
was extracted with 5 mL of methanol under ultrasonication
for 10 min. For LC–MS analysis, the prepared solution was
diluted to 1 lg/mL with methanol and passed through a
centrifugal filter (0.22 lm filter unit; EMD Millipore). For
NMR analysis, about 15 mg of the sample powder was
dissolved in 1 mL of deuterated DMSO.
Analytical conditions
Liquid chromatography–high-resolution mass spectrometry
(LC–HR-MS) analysis was carried out using a Waters
Acquity UPLC (Waters, Milford, MA, USA) coupled with
an AB Sciex TripleTOF 5600 detector (AB Sciex, Fram-
ingham, MA, USA). Separation was performed at 40 C
with an Acquity UPLC CSHTM C18 column
(10 cm 9 2.1 mm i.d., 1.7 lm particle diameter; Waters).
For gradient elusion the mobile phases 0.1 % formic acid
in water (A) and acetonitrile (B) were used with the time
program: 0–1.5 min, 2 % B; 1.5–6.5 min, 2–90 % B;
6.5–9.4 min, 90 % B; 9.4–9.5 min, 90–2 % B; 9.5–12 min,
2 % B. The flow rate was 0.4 mL/min. The Triple TOF
instrument was operated by electrospray ionization (ESI) in
the positive mode. Ion spray voltage, 5.5 kV; turbo spray
temperature, 600 C; nebulizer gas (Gas 1), 50 psi; heater
gas (Gas 2), 50 psi; curtain gas, 30 psi. Nitrogen was used
as the nebulizer and auxiliary gas. Typical information
dependent acquisition consisted of two steps: the acquisi-
tion of a survey full scan spectrum and then a tandem mass
spectrometry (MS/MS) experiment. Full scan experiment
was operated under the high resolution mode. The opti-
mized declustering potential and collision energy were set
at 80 and 5 V, respectively. In the second experiment, a
sweeping collision energy setting at 25 ± 15 V was applied
for collision-induced dissociation (CID) to obtain the
fragment ions from the ions in the preceding scan. The full
scan and the MS/MS experiment were both operated in the
mass range of m/z 100–1000. Injection volume was 1 lL.
Fig. 1 Structures of the newly detected compounds 1–4 as well as a
detected but known compound 5
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GC–MS analysis was performed using a Shimadzu 2010
gas chromatograph coupled with a QP2010 Plus mass
selective detector (Shimadzu, Kyoto, Japan). The extracts
were injected in split mode (1:20). Chromatographic sep-
aration was carried out on a DB-5 MS capillary column
(30 m 9 0.25 mm i.d., 0.25 lm film thickness; J&W Sci-
entific, Agilent Technologies, Palo Alto, CA, USA), and
helium at a constant flow rate of 1.0 mL/min was used as
the carrier gas. The initial column temperature (60 C) was
increased to 280 C at a rate of 20 C/min, and held at
280 C for 20 min, then ramped up to 300 C at a rate of
10 C/min, and finally held at 300 C for 20 min. The GC
injector and transfer line were maintained at 280 C and
250 C, respectively. Ionization energy was set at 70 eV
and positive ions were analyzed. Acquisition was carried
out in a scan mode range of m/z 35–500. Injection volume
was 1 lL.
The NMR spectra were obtained on an Avance III 400
spectrometer (Bruker, Bremen, Germany). Assignments
were made via 1H NMR, 13C NMR, distortionless
enhancement by polarization transfer (DEPT), HH corre-
lation spectroscopy (HH COSY), heteronuclear single-
quantum correlation spectroscopy (HSQC), and heteronu-
clear multiple-bond correlation spectroscopy (HMBC)
spectra.
Results and discussion
LC–HR-MS(/MS) and GC–MS analyses
of compounds 1–5
Firstly, exact molecular mass numbers of compounds 1–5
were confirmed by measurements in the full scan MS mode
using LC–HR-MS (Fig. 2). In addition, the accurate mas-
ses of the predominant product ions, obtained by the LC–
HR-MS/MS analysis (Fig. 3), provided further structural
information. Based on the obtained exact molecular mas-
ses, chemical formulae for protonated molecular ions and
product ions of compounds 1–5 are summarized in Table 1
together with calculated mass numbers. The errors between
the observed and theoretical mass numbers of all proto-
nated molecular ions and fragment ions were smaller than
5 ppm. The LC–MS fragmentation routes of these five
protonated compounds were proposed (Fig. 4).
For GC–MS analysis, total ion current chromatogram
(TIC) and electron ionization mass spectra of compounds
1–5 are shown in Figs. 5 and 6, respectively. In each of all
TIC chromatograms, only a single peak appeared (Fig. 5),
showing that each sample contained a target compound
with very high purity (probably more than 95 %). The GC–
MS fragmentation routes of these five compounds were
also proposed (Fig. 6).
Confirmation of compound 5 and its similarity
with compounds 1–4
Compound 5 is a known compound; its structure was
confirmed by the comparing its GC–MS and NMR data
with the data of compound AB-FUBINACA reported by
Uchiyama [9] and that in the GC–MS databases from
Cayman Chemical [11]. However, high-resolution mass
spectrum and MS/MS analysis of compound 5 have not
been reported and are shown in Table 1, Figs. 2e and 3e;
ions of [M ? Na]? and [M ? H]? were observed in the
ESI mass spectrum (Fig. 2e). In the product ion mass
spectrum (Fig. 3e), fragment ions at m/z 352.1465 (B5),
324.1511 (C5), and 253.0775 (D5) were formed by the
sequential loss of NH3, CO and amino-methylpropyl from
the protonated molecule (Fig. 4). The product ion mass
spectrum at m/z 109.0453 (E5) was a rearrangement pro-
duct of 1-fluoro-4-methylbenzene. The mass difference
value between product ions m/z 253.0775 (D5) and
109.0453 (E5) was 144.0324, which indicated the indazole-
carbaldehyde moiety.
Great similarities were found for the MS and NMR
spectra of compounds 1–5, which revealed the structure
similarity among these five compounds. For example, the
same neutral loss of ammonia [M ? H–NH3]
? were
observed in the LC–MS spectra (Figs. 2, 3), which corre-
sponds to the loss of amino side chain. In addition, the
same unsaturation degrees of 10 were observed. Therefore,
the structure of four unknown compounds 1–4 were elu-
cidated by comparing the MS and NMR spectral data with
the known compound 5.
Identification of compound 1
The LC–MS and GC–MS spectra of compound 1 are
shown in Figs. 2a, 3a, and 6a, respectively. The chemical
structure of compound 1 was predicted by comparing its
LC–MS and GC–MS spectra with those of compound 5
(AB-FUBINACA) (Figs. 2e, 3e, 6e). The accurate mass
spectrum of compound 1 was measured by LC–HR-MS/
MS in the positive mode. The ion peak observed at
m/z 365.1979 (A1) (Table 1) suggested that the protonated
molecular formula of the compound was C21H25N4O2
?
(calcd. 365.1972). Product ions at m/z 91.0546 (E1), 235.0870
(D1), and 320.1764 (C1) were found in the LC–HR-MS/MS
spectrum (Fig. 3a). The product ion at m/z 91.0546 (E1)
(predicted chemical formula: C7H7
?) indicated the presence
of an un-substituted benzyl moiety. The mass difference value
between product ions at m/z 235.0870 (D1) and 91.0546 (E1)
was 144.0324, which was identical with that between
253.0775 (D5) and 109.0453 (E5); compound 1 was deduced
to have the same indazole-carbaldehyde moiety as compound
5. The difference value between product ions C1
Forensic Toxicol (2016) 34:133–143 135
123
(C20H22N3O
?) and D1 (C15H11N2O
?) of compound 1 was
higher than that between product ions C5 (C19H19FN3O
?) and
D5 (C15H10FN2O
?) of compound 5 by 14 amu, which indi-
cated that compound 1 had an additional methylene moiety
than that group of compound 5. According to the LC–MS
spectral data, compound 1 was presumed to be N-(1-amino-
3,3-dimethyl-1-oxobutan-2-yl)-1-benzyl-1H-indazole-3-
carboxamide. The fragment ions at m/z 91, 235 and 320 of
compound 1 in the GC–MS spectrum supported the pre-
sumed structure of compound 1 (Fig. 6a).
The structure of compound 1 was further elucidated by
NMR analysis. The NMR spectra of this compound sug-
gested the presence of two amide carbonyl groups [dC
160.9, dH 7.60 (1-CONH) and dC 171.7, dH 7.72 and 7.26
(1¢¢¢-CONH2)] as shown in Table 2. The analyses by 1H and
13C NMR, DEPT, HH COSY, HSQC and HMBC spectra of
compound 1 revealed the presence of a 1-benzyl-1H-in-
dazole moiety (positions 30 to 70a and positions 100 to 700)
and an N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-carbox-
amide moiety (positions 1, 1-CONH, and 1¢¢¢-CONH2, and
positions 1¢¢¢–6¢¢¢). Unfortunately, no HMBC correlation
between the two moieties was observed. However, the
chemical shifts of corresponding carbons of compound 1
[dC 160.9 (C-1), 136.9 (C-30), 122.2 (C-30a), 121.7 (C-40),
122.7 (C-50), 127.0 (C-60), 110.7 (C-70), 140.7 (C-70a), 52.4
(C-100), and 171.7 (C-1¢¢¢)] were similar to those of AB-
FUBINACA [dC 161.2 (C-1), 137.1 (C-30), 122.3 (C-30a),
121.8 (C-40), 122.8 (C-50), 127.0 (C-60), 110.6 (C-70), 140.6
(C-70a), 51.6 (C-100), and 172.6 (C-1¢¢¢)] (Table 2). This
result suggested that carboxamide carbon (C-1, dC 160.9)
in the N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-carbox-
amide moiety was attached to the carbon at the 30-position
(dC 136.9) of the 1-benzyl-1H-indazole moiety as AB-
FUBINACA [9].
Finally, on the basis of mass spectra and NMR data as
shown above, the structure of compound 1 was determined
as an AB-FUBINACA analog [IUPAC: N-(1-amino-3,3-
dimethyl-1-oxobutan-2-yl)-1-benzyl-1H-indazole-3-carbox-
amide] and named ADB-BINACA (Fig. 1). Compound 1
has been reported to have an affinity for CB1 receptor [10],
Fig. 2 Mass spectra of compounds 1–5 obtained by liquid chromatography–high resolution-mass spectrometry (LC–HR-MS) in the single stage
mode
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but this is the first report in which compound 1 has been
detected in an illegal product.
Identification of compounds 2 and 3
The accurate mass spectra of compounds 2 and 3 were
measured by LC–HR-MS(/MS) in the positive mode. The
ion peak observed at m/z 368.1773 (A2) and 382.1931 (A3)
(Table 1) suggested that the protonated molecular formulae





Compound 2 was presumed to be N-(1-amino-3-methyl-
1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-carbox-
amide based on the product ion/fragment patterns of the
LC–HR-MS(/MS) analysis (Figs. 2b, 3b) and GC–MS
analysis (Fig. 6b). The observed product ions at
m/z 109.0452 (E2), 252.0825 (D2) and 351.1505 (B2) of
compound 2 (Fig. 3b) were similar to those of compound 5
(AB-FUBINACA) (Fig. 3e) obtained by LC–HR-MS/MS
analysis. The product ion at m/z 109.0452 (E2) (predicted
chemical formula: C7H6F
?) indicated the presence of a
fluorobenzyl moiety. By comparing the product ion at
m/z 252.0825 (D2) (predicted chemical formula: C16H11-
FNO?) in compound 2 (Fig. 3b) with the product ion at
m/z 253.0775 (D5) (predicted chemical formula: C15H10-
FN2O
?) in compound 5, one can predicted compound 2 has
an 1-pentyl-1H-indole-3-carbonyl moiety. The mass dif-
ference value between product ions at m/z 252.0825 (D2)
and 109.0452 (E2) also indicated the indole-carbonyl
moiety by comparing of the product ion pattern of a known
synthetic cannabinoid that has the same moiety, such as
ADBICA [7].
The structure of compound 2 was further elucidated by
GC–MS and NMR analyses. The fragment ions at m/z 109,
252 and 323 of compound 2 by GC–MS analysis (Fig. 6b)
and the observed 1H and 13C NMR, DEPT, HH COSY,
HSQC, and HMBC spectra for compound 2 suggested the
presence of a 1-(4-fluorobenzyl)-1H-indole moiety (posi-
tions 20 to 70a and positions 100–700) and an N-(1-amino-3-
Fig. 3 Spectra of product ion spectra of compounds 1–5 obtained by LC–HR-MS in the tandem (MS/MS) mode
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methyl-1-oxobutan-2-yl)-carboxamide moiety (positions 1,
1-CONH, and 1¢¢¢-CONH2, and positions 1¢¢¢–5¢¢¢) as shown
in Table 3. The key connections of the two moieties were
revealed by the HMBC correlations. Namely, the HMBC
correlations from the amide proton (1-CONH, dH 7.57) and
the indole proton (H-20, dH 8.35) to the carboxamide car-
bon atom (C-1, dC 163.9) suggested that the carboxamide
carbon (C-1) in the N-(1-amino-3-methyl-1-oxobutan-2-yl)-
carboxamide moiety was attached to the carbon at the 30-
position of the 1-(4-fluorobenzyl)-1H-indole moiety.
Therefore, the structure of compound 2 was determined to
be N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluoroben-
zyl)-1H-indole-3-carboxamide (AB-FUBICA).
The 13C NMR spectrum of compound 3 was very
similar to that of compound 2 except for a dimethylpropyl
moiety (position 2¢¢¢–6¢¢¢) as shown in Table 4. The dif-
ference between the molecular formulae of compound 3
(C22H24FN3O2) and compound 2 (C21H22FN3O2) is an
additional CH2. The observed 1D and 2D NMR spectra of
compound 3 suggested the presence of 1-(4-fluorobenzyl)-
1H-indole and N-(1-amino-3,3-dimethyl-1-oxobutan-2-
yl)-carboxamide moieties. That is, compound 3 may have
Fig. 4 Proposed fragmentation routes of protonated compounds 1–5
Table 1 Accurate mass numbers of the protonated molecular and predominant product ions, and their proposed chemical formulae obtained for
compounds 1–5 measured by liquid chromatography–high-resolution mass spectrometry (/mass spectrometry)
Compound RT (min)a Fragment Chemical formula Calculated mass Experimental mass Error (ppm)
(ADB-BINACA, 1) 5.56 A1 C21H25N4O2
? 365.1972 365.1979 1.9
B1 C21H22N3O2
? 348.1712 348.1719 2.0
C1 C20H22N3O
? 320.1757 320.1764 2.2
D1 C15H11N2O
? 235.0866 235.0870 1.7
E1 C7H7
? 91.0542 91.0546 4.4
(AB-FUBICA, 2) 5.24 A2 C21H23FN3O2
? 368.1769 368.1773 1.1
B2 C21H20FN2O2
? 351.1503 351.1505 0.6
D2 C16H11FNO
? 252.0819 252.0825 2.4
E2 C7H6F
? 109.0448 109.0452 3.7
(ADB-FUBICA, 3) 5.46 A3 C22H25FN3O2
? 382.1925 382.1931 1.6
B3 C22H22FN2O2
? 365.1660 365.1668 2.2
D3 C16H11FNO
? 252.0819 252.0824 2.0
E3 C7H6F
? 109.0448 109.0453 4.6
(AB-BICA, 4) 5.2 A4 C21H24N3O2
? 350.1863 350.1870 2.0
B4 C21H21N2O2
? 333.1598 333.1604 1.8
D4 C16H12NO
? 234.0913 234.0918 2.1
E4 C7H7
? 91.0542 91.0546 4.4
(AB-FUBINACA, 5) 5.34 A5 C20H22FN4O2
? 369.1721 369.1719 -0.5
B5 C20H19FN3O2
? 352.1461 352.1465 1.1
C5 C19H19FN3O
? 324.1507 324.1511 1.2
D5 C15H10FN2O
? 253.0772 253.0775 1.2
E5 C7H7F
? 109.0448 109.0453 4.6
a RT retention time
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an additional methyl group at the 3¢¢¢-position in the
structure of compound 2. Therefore, the structure of
compound 3 was deduced to be N-(1-amino-3,3-dimethyl-
1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-carbox-
amide (ADB-FUBICA). In addition, the product ions at
m/z 109.0453 (E3), 252.0824 (D3), and 365.1668 (B3)
obtained by the LC–HR-MS/MS analysis (Fig. 3c),
together with the fragment ions at m/z 109, 252 and 337
obtained by the GC–MS analysis (Fig. 6c) supported the
presumed structure.
This is the first case in which compounds 2 and 3 has been
detected in illegal products. Compounds 2 and 3 have been
reported to have an affinity for CB1 and CB2 receptors [7].
Identification of compound 4
LC–HR-MS analysis of compound 4 gave an ion peak at
m/z 350.1876, suggesting that the protonated molecular
formula of compound was C21H24N3O2
? (calcd.
350.1863). Compound 4 was presumed to be N-(1-amino-
3-methyl-1-oxobutan-2-yl)-1-benzyl-1H-indole-3-carbox-
amide based on the product ion/fragment patterns of the
LC–HR-MS(/MS) analysis (Fig. 3d) and GC–MS analysis
(Fig. 6d). The LC–HR-MS/MS profile of compound 4 was
very similar to that of compound 2 (Fig. 3b). The product
ion at m/z 91.0546 (E4) (predicted chemical formula:
C7H7
?) indicated the presence of an un-substituted benzyl
moiety. In addition, the fragment ions of compound 4 at
m/z 349, 305, 234, 91 in GC–MS spectrum were all lower
than those of compound 2 (367, 323, 252, 109) by 18 amu,
which indicated the difference between compounds 4 and 2
was a single fluoro-substitution.
The structure of compound 4 was further elucidated by
NMR analysis. The 13C NMR spectrum of compound 4
was very similar to that of compound 2 except for a benzyl
moiety (positions 200 to 700) as shown in Table 5. The dif-
ference between the molecular formulae of compound 4
(C21H23N3O2) and compound 2 (C21H22FN3O2) is an
Fig. 5 Total ion current chromatogram for samples containing compounds 1–5 obtained by gas chromatography–electron ionization-mass
spectrometry (GC–EI-MS)
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additional hydrogen atom in the place of the absent fluorine
atom. The observed 1H and 13C NMR, DEPT, HH COSY,
HSQC, and HMBC spectra for compound 4 suggested the
presence of 1-benzyl-1H-indole and N-(1-amino-3-methyl-
1-oxobutan-2-yl)-carboxamide moieties. Compound 4 may
have a benzyl group instead of the 4-fluorobenzyl group in
the structure of compound 2.
Finally, on the basis of mass spectral and NMR data as
shown above, the structure of compound 4 was finally
determined as an AB-FUBICA analog [IUPAC: N-(1-
amino-3-methyl-1-oxobutan-2-yl)-1-benzyl-1H-indole-3-
carboxamide], and named AB-BICA (Fig. 1).
This is the first report in which compound 4 has been
reported and detected. Compound 4 is a novel cannabi-
mimetic substance; its chemical and pharmacological data
have not been reported previously. However, para-F-sub-
stituted benzyl indole analog of compound 4 has been
reported as a cannabinoid CB1 and CB2 receptor modulator
[7]. Therefore, it is assumed that compound 4 may have a
similar cannabimimetic activity.
Conclusions
In this study, four new synthetic cannabimimetic indazole
and indole derivatives, ADB-BINACA (1), AB-FUBICA
(2), ADB-FUBICA (3), and AB-BICA (4) have been
identified as NPSs in illegal products seized in a clandes-
tine laboratory. Chemical structures of these compounds
were elucidated by LC–HR-MS/MS, GC–MS and NMR
spectroscopy. Compound 4 has neither been reported as a
synthetic compound in the literature nor as an adulterant in
dubious products, and was an entirely novel compound.
Compounds 1–3 have been reported to have potent binding
affinity for cannabinoid CB1 and CB2 receptors, but have
not been detected in illegal products. Because of the lim-
ited pharmacological and toxicological information for
Fig. 6 Mass spectra of compounds 1–5 obtained by GC–EI-MS together with their probable fragmentation modes
140 Forensic Toxicol (2016) 34:133–143
123
Table 2 Nuclear magnetic resonance (NMR) data for compound 1
No. Compound 1a AB-FUBINACAb
13C 1H HMBCc 13C
1 160.9 – – 161.2
30 136.9 – – 137.1
30a 122.2 – – 122.3
40 121.7 8.19, 1H, d-like, J = 8.4 Hz 30, 60, 70a 121.8
50 122.7 7.29, 1H, m, overlapped 30a, 70 122.8
60 127.0 7.45, 1H, ddd, J = 8.4, 7.0, 1.2 Hz 40, 70a 127.0
70 110.7 7.77, 1H, d-like, J = 8.8 Hz 30a, 50 110.6
70a 140.7 – – 140.6
100 52.4 5.79, 2H, s 70a, 200, 300/700 51.6
200 136.7 – – 133.0, d, J = 2.9 Hz
300/700 127.2 7.26, 2H, m, overlapped 100, 500 129.5, d, J = 8.7 Hz
400/600 128.7 7.32, 2H, m, overlapped 200, 500 115.5, d, J = 21.7 Hz
500 127.7 7.27, 1H, m, overlapped 300/700 161.6, d, J = 242.8 Hz
1¢¢¢ 171.7 – – 172.6
2¢¢¢ 58.7 4.48, 1H, d, J = 9.6 Hz 1, 1¢¢¢, 3¢¢¢, 4¢¢¢/5¢¢¢/6¢¢¢ 56.9
3¢¢¢ 34.5 – – 31.2
4¢¢¢/5¢¢¢/6¢¢¢ 26.6 1.00, 9H, s 2¢¢¢, 3¢¢¢ 19.4, 18.1
1-CONH – 7.60, 1H, d, J = 10.0 Hz 1, 1¢¢¢, 2¢¢¢ –
1¢¢¢-CONH2 – 7.72, 1H, brs 1¢¢¢ –
– 7.26, 1H, brs, overlapped 1¢¢¢, 2¢¢¢ –
a Recorded in dimethyl sulfoxide (DMSO-d6) at 400 MHz (
1H) and 100 MHz (13C), respectively; data in d ppm
b Ref [9], recorded in DMSO-d6 at 150 MHz (
13C), respectively; data in d ppm
c HMBC heteronuclear multiple-bond correlation spectroscopy. J = 8 Hz; the proton signal correlated with the indicated carbons
Table 3 NMR data for
compound 2
No. 13C 1H HMBC
1 163.9 – –
20 131.6 8.35, 1H, s 1, 30, 30a, 70a, 100
30 110.0 – –
30a 126.6 – –
40 121.1 8.11, 1H, m 30, 60, 70a
50 120.8 7.15, 1H, m, overlapped 30a, 70
60 122.1 7.17, 1H, m, overlapped 40, 70a
70 110.6 7.53, 1H, m, overlapped 30a, 50
70a 136.0 – –
100 48.7 5.45, 2H, m 20, 70a, 200, 300/700
200 133.7, d, J = 3.0 Hz – –
300/700 129.3, d, J = 8.4 Hz 7.33, 2H, m 100, 400/600, 500
400/600 115.4, d, J = 21.2 Hz 7.16, 2H, m, overlapped 200, 300/700, 500
500 161.5, d, J = 242.0 Hz – –
1¢¢¢ 173.5 – –
2¢¢¢ 57.4 4.36, 1H, dd, J = 8.8, 7.2 Hz 1, 1¢¢¢, 3¢¢¢, 4¢¢¢, 5¢¢¢
3¢¢¢ 30.4 2.09, 1H, m 2¢¢¢, 4¢¢¢, 5¢¢¢
4¢¢¢ 19.5 0.95, 3H, d, J = 6.4 Hz 2¢¢¢, 3¢¢¢, 5¢¢¢
5¢¢¢ 18.5 0.94, 3H, d, J = 6.8 Hz 2¢¢¢, 3¢¢¢, 4¢¢¢
1-CONH – 7.57, 1H, d, J = 8.8 Hz, overlapped 1, 2¢¢¢
1¢¢¢-CONH2 – 7.48, 1H, brs 1¢¢¢
– 7.07, 1H, brs 1¢¢¢, 2¢¢¢
Recorded under the same conditions as specified in Table 2
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Table 5 NMR data for
compound 4
No. 13C 1H HMBC
1 164.0 – –
20 131.7 8.38, 1H, s 1, 30, 30a, 70a, 100
30 109.9 – –
30a 126.6 – –
40 121.1 8.12, 1H, m 30, 60, 70a
50 120.8 7.14, 1H, m, overlapped 30a, 70
60 122.1 7.16, 1H, m, overlapped 40, 70a
70 110.7 7.52, 1H, m, overlapped 30a, 50
70a 136.1 – –
100 49.5 5.46, 2H, m 20, 70a, 200, 300/700
200 137.5 – –
300/700 127.2 7.27, 2H, m, overlapped 100, 500
400/600 128.6 7.33, 2H, m 200, 500
500 127.6 7.27, 1H, m, overlapped 300/700
1¢¢¢ 173.5 – –
2¢¢¢ 57.5 4.36, 1H, dd, J = 8.8, 7.2 Hz 1, 1¢¢¢, 3¢¢¢, 4¢¢¢, 5¢¢¢
3¢¢¢ 30.4 2.09, 1H, m 1¢¢¢, 2¢¢¢, 4¢¢¢, 5¢¢¢
4¢¢¢ 19.5 0.95, 3H, d, J = 6.8 Hz 2¢¢¢, 3¢¢¢, 5¢¢¢
5¢¢¢ 18.5 0.94, 3H, d, J = 6.8 Hz 2¢¢¢, 3¢¢¢, 4¢¢¢
1-CONH – 7.59, 1H, d, J = 8.8 Hz 1, 2¢¢¢
1¢¢¢-CONH2 – 7.50, 1H, brs, overlapped 1¢¢¢
– 7.06, 1H, brs 1¢¢¢, 2¢¢¢
Recorded under the same conditions as specified in Table 2
Table 4 NMR data for
compound 3
No. 13C 1H HMBC
1 163.7 – –
20 131.9 8.42, 1H, s 1, 30, 30a, 70a, 100
30 110.0 – –
30a 126.5 – –
40 120.9 8.08, 1H, m 30, 60, 70a
50 120.8 7.16, 1H, m, overlapped 30a, 70
60 122.1 7.17, 1H, m, overlapped 40, 70a
70 110.8 7.53, 1H, m 30a, 50
70a 136.0 – –
100 48.7 5.46, 2H, m 20, 70a, 200, 300/700
200 133.7, d, J = 3.0 Hz – –
300/700 129.3, d, J = 8.2 Hz 7.34, 2H, m 100, 400/600, 500
400/600 115.4, d, J = 21.3 Hz 7.16, 2H, m, overlapped 200, 300/700, 500
500 161.5, d, J = 242.0 Hz – –
1¢¢¢ 172.5 – –
2¢¢¢ 59.2 4.48, 1H, d, J = 9.6 Hz 1, 1¢¢¢, 3¢¢¢, 4¢¢¢/5¢¢¢/6¢¢¢
3¢¢¢ 34.1 – –
4¢¢¢/5¢¢¢/6¢¢¢ 26.9 1.02, 9H, s 2¢¢¢, 3¢¢¢
1-CONH – 7.25, 1H, d, J = 9.2 Hz 1, 1¢¢¢, 2¢¢¢
1¢¢¢-CONH2 – 7.56, 1H, brs 1¢¢¢
– 7.11, 1H, brs 1¢¢¢, 2¢¢¢
Recorded under the same conditions as specified in Table 2
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most of these cannabimimetic compounds, it is difficult to
predict the health risks associated with their use. Hence,
constant monitoring and rapid identification of newly
tributed NPSs are necessary to prevent drug abuse and
serious health risks.
Considering the result of this study, it is obvious that
new types of synthetic cannabinoids emerge rapidly, and
their combinations in illegal products can be expected to
become more and more diverse. The provision of timely
and objective information on NPSs and their current trends
are thus essential to prevent abuse of drugs.
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